NYSE: BSX · Medical Devices
Boston Scientific (BSX) fair value: undervalued or overvalued?
As of 3 Oct 2026, Faircurve's model values Boston Scientific (BSX) at $46.67 a share. The stock last closed at $42.60, which puts the model's fair value 9.6% above the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 2 Oct 2026. Boston Scientific Corporation.
Faircurve Insights · 3 Oct 2026
Boston Scientific Corporation operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties.
On 3 Oct 2026, Faircurve's model gave a fair value of $46.67 a share, the midpoint of 2,000 simulations. This fair value moved -2.7% from the previous run on 26 Sep 2026, which gave $47.98. The model's calibrated range over 63 trading days is $37.76 to $52.01, and ranges built this way held the price 60% of the time at this horizon. The evidence grade is Medium.
The company's overall quality score is 64 out of 100 against comparable companies. Its profitability score is 71, earnings quality is 52, growth quality is 65, capital discipline is 85, balance sheet is 45, and stability is 57. The model compares it with Edwards Lifesciences Corporation, Stryker Corporation, Medtronic plc, DexCom, Inc., GE HealthCare Technologies Inc., Abbott Laboratories, Zimmer Biomet Holdings, Inc., and Penumbra, Inc. The median size of moves around the last 8 earnings reports, ignoring direction, was 3.1%.
Written from the figures on this page for the 3 Oct 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
What price range does the model give BSX?
The calibrated range for BSX over 63 trading days is $37.76 to $52.01. It sits around the last close, and its width comes from the volatility that BSX's own options imply (45% a year), calibrated weekly against realised prices (n = 3,562 past valuations, refreshed 3 Oct 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $31.83 to $66.15. In 58% of the simulations the fair value came out above the price the model ran on.
How does BSX score on business quality?
Boston Scientific's overall quality score is 64 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 71 | 11.5%ROIC | 10.3% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 52 | 0.99xFCF / net income | 1.13x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analyst estimate revisions. | 65 | 19.9%Revenue growth, trailing | 9.8% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 85 | 3.2%Net buybacks / market value | 0.7% |
| Balance sheetNet debt to EBITDA and interest coverage. | 45 | 2.13xNet debt / EBITDA | 1.26x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 57 | 1.1 ptsEBITDA margin downside volatility, 5y | 0.9 pts |
How does BSX compare with similar companies?
The companies in medical devices closest to Boston Scientific in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| EW Edwards Lifesciences Corporation | $85.15 | $70.87 | -16.8% | Overvalued |
| SYK Stryker Corporation | $275.43 | $270.59 | -1.8% | Fairly valued |
| MDT Medtronic plc | $86.38 | $77.78 | -10.0% | Fairly valued |
| DXCM DexCom, Inc. | $85.36 | $85.74 | +0.4% | Fairly valued |
| GEHC GE HealthCare Technologies Inc. | $64.29 | $68.52 | +6.6% | Fairly valued |
| ABT Abbott Laboratories | $97.50 | $96.55 | -1.0% | Fairly valued |
| ZBH Zimmer Biomet Holdings, Inc. | $88.29 | $106.90 | +21.1% | Undervalued |
| PEN Penumbra, Inc. | $317.55 | $284.11 | -10.5% | Fairly valued |
When does BSX report earnings, and how has the stock reacted?
Boston Scientific's next earnings report is scheduled for 28 Oct 2026. Companies can move their dates.
Options prices on 2 Oct 2026 imply a move of about 5.4% in either direction through the nearest expiry, about 13 days out. That is the size the market is pricing, not a direction. BSX's 30 day implied volatility works out to about 13.1% over one month.
How BSX moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 3.1%.
| Report date | Two session move |
|---|---|
| 29 Jul 2026 | -0.1% |
| 22 Apr 2026 | +10.4% |
| 4 Feb 2026 | -15.3% |
| 22 Oct 2025 | +2.5% |
| 23 Jul 2025 | +3.0% |
| 23 Apr 2025 | +6.4% |
| 5 Feb 2025 | +1.4% |
| 23 Oct 2024 | -3.3% |
Boston Scientific at a glance
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the.
- Market value
- $63.3B
- Sector
- Healthcare
- Industry
- Medical Devices
- Revenue expected, next twelve months
- $21.9B
- Consensus revenue growth, next fiscal year
- +5.8%
- Analysts with estimates
- 15
- Beta to the US market
- 0.15
- First valued by Faircurve
- 1 May 2026
How the fair value is worked out: the model prices Boston Scientific on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 26 Sep 2026 the model's fair value for BSX was $47.98. As of 3 Oct 2026 it is $46.67, a change of -2.7%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Boston Scientific's valuation
Is Boston Scientific stock undervalued or overvalued?
On Faircurve's model, BSX reads as Fairly valued as of 3 Oct 2026. The model's fair value is $46.67 a share against a last close of $42.60, a gap of +9.6%.
What is BSX's fair value?
$46.67 a share as of 3 Oct 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $31.83 to $66.15.
What price range does the model give BSX?
$37.76 to $52.01 over 63 trading days. Ranges built this way held the price 60% of the time across 3,562 past valuations, refreshed 3 Oct 2026.
When does Boston Scientific report earnings next?
The next report is scheduled for 28 Oct 2026. Companies can move their dates.
How much has BSX moved on past earnings reports?
Across its last 8 reports the median two session move was 3.1%, ignoring direction. The largest was -15.3% around the report of 4 Feb 2026.
How confident is the model in this valuation?
The model's evidence grade for BSX is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.